|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 01/20/2015 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Genetically Engineered (GE) Animals
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
H.R. 4432: Safe and Accurate Food Labeling Act
Foreign Agricultural Biotechnology Laws and Regulations
China Biotechnology Regulations
Asynchrony of International Approvals
Funding for Biomass Crop Assistance Program
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Transatlantic Trade and Investment Partnership
Ag-Biotech Issues
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
Joseph |
Damond |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Brent |
DelMonte |
|
|
|
. |
. |
|
|
|
. |
. |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for FDA
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Centers for Disease Control and Prevention Vaccine Programs
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for National Institutes of Health
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Biomass Crop Assistance Program
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Sequestration of PDUFA Fees
HR 2725: Food and Drug Administration Safety over Sequestration Act of 2013
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Energy Basic Research Funding
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Biofuels
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Cartier |
Esham |
|
|
|
Andrew |
Emmett |
|
|
|
Brent |
Del Monte |
|
|
|
Derrick |
White |
|
|
|
Kelly |
Cappio |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Clinical Trial Data Sharing and Disclosure
Canadian Policies
European Policies
Patent Reform
H.R. 2024: End Anonymous Patents Act
H.R. 3309: Innovation Act of 2013
H.R. 845: The SHIELD Act of 2013
S. 1013: Patent Abuse Reduction Act of 2013
S. 1720: Patent Transparency and Improvements Act of 2013
Targeting Rogue and Opaque Letters (TROL) Act of 2014 (Discussion Draft)
Implementation of H.R. 1249: The America Invents Act of 2011
FTC Regulation of Patent Demand Letters (Senator Commerce Committee Discussion Draft)
World Trade Organization Special 301 Submissions
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
Intellectual Property Issues
Trade Promotion Authority
H.R. 3830/S. 1900: Bipartisan Congressional Trade Priorities Act of 2014
Patenting of Biological Inventions
PTO Examination Guidelines
DNA Patenting and Licensing
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derrick |
White |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
|
Charles |
Fritts |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Review of Biotech Products
Genetically Engineered (GE) Animals
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
H.R. 4432: Safe and Accurate Food Labeling Act
Funding for FDA
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Drug Evaluation and Review
Implementation of the FDA Safety and Innovation Act
Biosimilars
Colombia Biologics Regulations
Implementation of Affordable Care Act
Interchangeability and Pharmacy Substitution
Naming
Sunshine Act Implementation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Agriculture - Dept of (USDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
Cartier |
Esham |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Derrick |
White |
|
|
|
Dana |
O'Brien |
|
|
|
Catharine |
Harris |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
|
Matthew |
O'Mara |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeffrey |
Peters |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Funding for Biofuels
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Biofuels
Accelerated Depreciation Extension
Implementation of the Agricultural Act of 2014
Production Tax Credit Extension
Renewable Fuel Standard
S. 2260: EXPIRE Act of 2014
Renewable Chemicals/Bio-based Products
Expansion of Master Limited Partnerships to Renewable Chemicals
Implementation of the Agricultural Act of 2014
H.R. 1696/S. 795: Master Limited Partnerships Parity Act
H.R. 2421: Renewable Chemicals Parity Act
S. 2260: EXPIRE Act of 2014
Funding for Biomass Crop Assistance Program
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Energy Basic Research Funding
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
Del Monte |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Review and Labeling of Food Derived From Biotechnology
H.R. 4432: Safe and Accurate Food Labeling Act
Genetically Engineered (GE) Animals
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Amendment on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
Matthew |
O'Mara |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Funding for Biofuels
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Biofuels
Accelerated Depreciation Extension
Implementation of the Agricultural Act of 2014
Production Tax Credit Extension
Renewable Fuel Standard
S. 2260: EXPIRE Act of 2014
Renewable Chemicals/Bio-based Products
Expansion of Master Limited Partnerships to Renewable Chemicals
Implementation of the Agricultural Act of 2014
H.R. 1696/S. 795: Master Limited Partnerships Parity Act
H.R. 2421: Renewable Chemicals Parity Act
S. 2260: EXPIRE Act of 2014
Funding for Biomass Crop Assistance Program
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Energy Basic Research Funding
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Renewable Chemicals/Bio-based Products
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
Del Monte |
|
|
|
. |
. |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Affordable Care Act Implementation
Third Party Support of Patient Premiums and Cost-Sharing Obligations
21st Century Cures Initiative
Biomarkers and Regulatory Science Improvements
Communication with Healthcare Professionals
Expanded Access to Investigational Drugs
Expedited Pathways
FDA Hiring Flexibility
FDA Management and Financial Accountability
Innovation Incentives
Longitudinal Study of Chronic Diseases
Patient Access to Approved Drugs
Patient-Focused Drug Development
Use of Real-World Evidence
Vaccine and Anti-Microbial Resistance Product Development and Incentives
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
Biosimilars
Biosimilar User Fee Act Implementation
Colombia Biologics Regulations
Implementation of Affordable Care Act
Interchangeability and Pharmacy Substitution
Naming
Patent Certification
Funding for National Institutes of Health
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Centers for Disease Control and Prevention Vaccine Programs
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
340B Drug Pricing Program
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Implementation of Affordable Care Act
Program Implementation & Oversight
Funding for FDA
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Independent Payment Advisory Board
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
TransPacific Partnership
Regulatory Transparency
Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
Regulatory Harmonization
Reimbursement Issues
Intellectual Property Issues
Reimbursement for Innovative Products
H.R. 1416: Cancer Patient Protection Act of 2013
Medicare Part B Physician-Administered Products
Medicare Part D Prescription Drug Program
CMS Proposed Rule on Protected Classes
Sequestration of PDUFA Fees
HR 2725: Food and Drug Administration Safety over Sequestration Act of 2013
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Drug Evaluation and Review
Implementation of the FDA Safety and Innovation Act
Orphan Drug Act Tax Credit
Clinical Trial Data Sharing and Disclosure
Canadian Policies
European Policies
Sunshine Act Implementation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Natl Security Council (NSC), Office of Management & Budget (OMB), U.S. Trade Representative (USTR), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catharine |
Harris |
|
|
|
Andrew |
Emmett |
|
|
|
Charles |
Fritts |
|
|
|
Joseph |
Damond |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Kelly |
Cappio |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
|
Jeffrey |
Peters |
|
|
|
Charles |
Crain |
|
|
|
Shelley |
Mui-Lipnik |
|
|
|
Hans |
Sauer |
|
|
|
Kathleen |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
EPA Regulation of Biotechnology
17. House(s) of Congress and Federal agencies Check if None
Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rina |
Singh |
|
|
|
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
21st Century Cures Initiative
Patient Access to Approved Drugs
Reimbursement for Innovative Products
H.R. 1416: Cancer Patient Protection Act of 2013
Medicare Part B Physician-Administered Products
Medicare Part D Prescription Drug Program
CMS Proposed Rule on Protected Classes
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sara |
Radcliffe |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Brent |
DelMonte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
|
Laurel |
Todd |
|
|
|
Jeffrey |
Peters |
|
|
|
Derrick |
White |
|
|
|
Catharine |
Harris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
21st Century Cures Initiative
Longitudinal Study of Chronic Diseases
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brent |
DelMonte |
|
|
|
Kathleen |
Holcombe |
|
|
|
Jeffrey |
Peters |
|
|
|
Cartier |
Esham |
|
|
|
Catharine |
Harris |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Sara |
Radcliffe |
|
|
|
Tracey |
LaTurner |
|
|
|
Kelly |
Cappio |
|
|
|
Tom |
DiLenge |
|
|
|
Phyllis |
Arthur |
|
|
|
. |
. |
|
|
|
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
H.R. 1564/S. 1526: The Audit Integrity and Job Protection Act
Capital Formation Investment Incentives
Reform of Capital Gains Rules
Reform of Net Operating Loss Rules
Reform of Passive Loss Rules
S. 1658: The Start-up Jobs and Innovation Act
S. 2260: EXPIRE Act of 2014
H.R. 4855, the PARTNER Act
Expansion of Exemption under SEC Regulation A
Proposed SEC Rule on Reg A+
H.R. 4565: Startup Capital Modernization Act
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
H.R. 2629: The Fostering Innovation Act
XBRL Exemption for Small Public Companies
H.R. 5405: The Promoting Job Creation and Reducing Small Business Burdens Act
H.R. 4164: Small Company Disclosure Simplification Act
Stock Exchange Tick Size
H.R. 5405: Promoting Job Creation and Reducing Small Business Burdens Act
H.R. 3448: The Small Cap Liquidity Reform Act
Capital Market Enhancements
H.R. 4568: Small Business Freedom to Grow Act
H.R. 3623: Improving Access to Capital for Emerging Growth Companies Act
H.R. 4697: To require the SEC to revise the definition of a WKSI to reduce the worldwide market
value threshold under the definition
H.R. 4569: Disclosure Modernization and Simplification Act
H.R. 4571: To direct the SEC to revise its rules so as to increase the threshold amount for
requiring issuers to provide certain disclosures relating to compensatory benefits plans
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Renewable Chemicals/Bio-based Products
S. 2260: EXPIRE Act of 2014
Biofuels
Accelerated Depreciation Extension
Production Tax Credit Extension
S. 2260: EXPIRE Act of 2014
Research & Development Tax Credit Reforms
Extension
Permanency
H.R. 4438: American Research & Competitiveness Act of 2014
H.R.119: To amend the Internal Revenue Code to make permanent the credit for increasing
research activities
S. 2260: EXPIRE Act of 2014
S. 2715: The COMPETE Act
S. 193: The Start-up Innovation Credit Act
Capital Formation Investment Incentives
Reform of Capital Gains Rules
Reform of Net Operating Loss Rules
Reform of Passive Loss Rules
S. 2260: EXPIRE Act of 2014
H.R. 4855, the PARTNER Act
S. 1658: The Start-up Jobs and Innovation Act
HR 4855: To amend the Internal Revenue Code of 1986 to provide an exception from the passive
loss rules for investments in high technology research small business pass-thru entities
Tax Reform
Orphan Drug Act Tax Credit
Controlled Foreign Corporation Look-Through Rule Extension
S. 2260: EXPIRE Act of 2014
Inversions
H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Erick |
Lutt |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Derrick |
White |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Charles |
Crain |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Foreign Agricultural Biotechnology Laws and Regulations
China Biotechnology Regulations
Asynchrony of International Approvals
World Trade Organization Special 301 Submissions
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
Regulatory Transparency
Transatlantic Trade and Investment Partnership
Ag-Biotech Issues
Intellectual Property Issues
Regulatory Harmonization
Reimbursement Transparency
Biosimilars
Colombia Biologics Regulations
Clinical Trial Data Sharing and Disclosure
Canadian Policies
European Policies
Trade Promotion Authority
H.R. 3830/S. 1900: Bipartisan Congressional Trade Priorities Act of 2014
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Anna |
Weinstein |
|
|
|
Brent |
DelMonte |
|
|
|
Joseph |
Damond |
|
|
|
Jeanne |
Haggerty |
|
|
|
Charles |
Fritts |
|
|
|
Matthew |
O'Mara |
|
|
|
Dana |
O'Brien |
|
|
|
Derrick |
White |
|
|
|
Hans |
Sauer |
|
|
|
Cathleen |
Enright |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
HOM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |